Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 166Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma 23Neoplasms, Plasma Cell 21Leukemia 21Recurrence 20Burkitt Lymphoma 18Lymphoma, Non-Hodgkin 15Neoplasms 14Lymphoma, Mantle-Cell 14Immunoglobulin Light-chain Amyloidosis 14Nausea 13Lymphoma, Large B-Cell, Diffuse 13Vomiting 12Breast Neoplasms 12Hodgkin Disease 11Waldenstrom Macroglobulinemia 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Follicular 9Amyloidosis 9Lymphoma, B-Cell, Marginal Zone 8Leukemia, Myeloid, Acute 8Smoldering Multiple Myeloma 7Neoplasm Metastasis 7Leukemia, Biphenotypic, Acute 6Hematologic Neoplasms 6Blast Crisis 6Prostatic Neoplasms 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, B-Cell 5

Interventions

siltuximab 4fludarabine 3Cyclophosphamide 3fludarabine phosphate 2Interleukin 1 Receptor Antagonist Protein 2AP 1903 reagent 2tocilizumab 1talquetamab 1axicabtagene ciloleucel 1Neuropsychological Tests 1Metoprolol 1Magnetic Resonance Spectroscopy 1Leukapheresis 1Infliximab 1Etanercept 1Dexamethasone 1Contrast Media 1Calcium Dobesilate 1Blood Specimen Collection 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cytokine Release Syndrome × Calcium Dobesilate × Clear all
NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Recruiting
100 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡